ClinicalTrials.gg
Status unknownNCT01547091RAUpdated Jun 27, 2013

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis

A Phase 1/2 interventional study of Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) and Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) in Rheumatoid Arthritis, sponsored by Alliancells Bioscience Corporation Limited. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-06-27.

Sponsored by Alliancells Bioscience Corporation Limited · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
75th of 217
200 · median 134
Started
2013
with 5 others
Phase 1/2
4 of 249
1 open now
Registered
27th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 75th largest by planned enrollment of the 217 interventional ones that give a count, is one of 6 that started in 2013, is one of 4 in phase 1/2, and was the 27th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that umbilical cord-derived mesenchymal stem cell (UC-MSCs) has anti-inflammatory effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of UC-MSCs transplantation in treatment of rheumatoid arthritis.

Read the detailed description

This study was supported by the National Natural Science Foundation of China (30872618),The Shanxi Province Social Development Public Relations Project (2012K13-02-35), and The Military Medicine and Public Health Plan (CLZ120GA23)

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Mesenchymal Stem Cells
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients fulfilled the classification criteria (2010) for rheumatoid arthritis, man or woman aged from 18 to 70 years old.
  • Patients must be informed of the nature of this study and give written in accordance with the institutional and hospital guidelines.
  • Women of may not participate unless they have agreed to use an effective method while on this trial. Women of must have a pregnancy test performed within 72 hours prior to initiation of treatment.

Exclusion criteria

Exclusion Criteria:

  • Any history of ongoing, significant or recurring infections.
  • Any active inflammatory diseases other than RA.
  • Significant cardiac or pulmonary disease.
  • End-stage renal failure.
  • Pregnant or nursing women may not participate due to the possibility of fetal harm or harm to nursing infants from this treatment regimen.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    UC-MSCs Treatment

    Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.

    Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)

  • Active comparator
    DMARDS

    Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).

    Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)

  • Active comparator
    UC-MSC+DMARDS

    Patients will be treated in combination with UC-MSC and DMARDS.

    Biological: UC-MSC+DMARDS

Interventions

  • BiologicalUmbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)

    -The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.

  • DrugRheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)

    -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.

  • BiologicalUC-MSC+DMARDS

    Drug page: Solizmestrocel

    The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.

06

What researchers measure

Primary outcomes

  1. Safety of MSC treatment.

    Adverse Events will be recorded in a patient or clinical investigation subject who administers MSC and will be evaluated a causal relationship with the treatment.

    Time frame: six months

Secondary outcomes

  1. RA Serology

    Rheumatoid Factor, C-reactive protein

    Time frame: 1, 3 and 6 months

  2. Disease Activity Score (DAS 28) Index Mean Change From Baseline

    Time frame: 1, 3 and 6 months

  3. Patient's assessment of pain.

    Time frame: 1, 3 and 6 months

07

Study locations

1 of 1 sites recruiting
  • The 323 Hospital of Chinese People's Liberation Army
    Xi'an, Shaanxi 710054, China
    Recruiting
    • Liming Wang, MD · Contactwanglm@fmmu.edu.cn · 86-29-84756502
    • Liming Wang, MD · Principal investigator
08

References and documents

Publications

  • Wang H, Wu M, Liu Y. Are mesenchymal stem cells major sources of safe signals in immune system? Cell Immunol. 2012;272(2):112-6. doi: 10.1016/j.cellimm.2011.10.010. Epub 2011 Oct 29. PubMed 22138499 ↗
  • Wang L, Ji H, Zhou J, Xie J, Zhong Z, Li M, Bai W, Li N, Zhang Z, Wang X, Zhu D, Liu Y, Wu M. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013;2013:146347. doi: 10.1155/2013/146347. Epub 2013 Mar 3. PubMed 23533920 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2012
First posted
Mar 7, 2012
Start
Apr 2013
Primary completionEst.
Oct 2014
CompletionEst.
Dec 2014
Last update
Jun 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01547091
Lead sponsor
Alliancells Bioscience Corporation Limited
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Apr 2013
Primary completion
Oct 2014 (estimated)
Completion
Dec 2014 (estimated)
Last update
Jun 27, 2013

Study contacts

Mingyuan Wu, MD,PhD
Contact
mingyuan-wu@ouhsc.edu
86-10-63188123
Haijie Ji, MD
Contact
jihaijie82@sohu.com
86-10-63188853
Mingyuan Wu, MD,PhD
principal investigator · Eastern Union Stem Cell & Gene Engineering Co.,Ltd,Alliancells Biosciences Co., Ltd
Yongjun Liu, MD,PhD
principal investigator · Alliancells Biosciences Co., Ltd
Liming Wang, MD
study director · The 323 Hospital of Chinese People's Liberation Army
Haijie Ji, MD
principal investigator · Alliancells Biosciences Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion